解读肌肉疾病患者中肌联蛋白基因变异
该病例系列对504例肌营养不良、先天性肌病或其他骨骼肌疾病患者进行靶向重测序,识别出9例肌联蛋白病患者及4例可能致病性TTN变异患者;多数突变为既往未报道,但所有变异均需结合临床与分子学仔细评估,杂合截短变异或单一错义改变不足以诊断肌联蛋白病,作者提出针对TTN遗传结果临床解读的特定流程。
要点
- 在504例骨骼肌疾病患者中识别出9例肌联蛋白病及4例可能致病性TTN变异患者。
- 杂合截短变异或单一错义改变不足以诊断肌联蛋白病。
- TTN变异解读常需深度表型分析及信使RNA和蛋白研究。
核心结论
- TTN变异的解读常需进一步分析,包括临床表型的全面评估(深度表型分析)以及信使RNA和蛋白研究。
- 作者提出针对肌联蛋白遗传结果临床解读的特定流程。
研究设计与样本
- 病例系列,对来自10个临床中心的504例肌营养不良、先天性肌病或其他骨骼肌疾病患者进行靶向重测序。
- 患者入组时间为2012年4月至2013年12月,所有患者经广泛检查(包括候选基因Sanger测序)后仍未确诊。
- 数据分析于2013年9月至2017年1月进行,测序数据使用内部自定义生物信息学流程分析。
主要发现
- 9例新发肌联蛋白病患者中,5例(55.5%)为男性,平均(SD)发病年龄为25(15.8)岁(范围0-46岁)。
- 4例其他可能致病性TTN变异患者(3男1女)中,2例(50%)患有先天性肌病,2例(50%)患有缓慢进展的远端肌病,发病于第二个十年。
- 多数识别出的突变为既往未报道的变异。
关键数值与推荐
- 所有变异,包括已描述的突变,均需对先证者及亲属进行仔细的临床和分子学评估。
- 杂合截短变异或单一错义改变不足以诊断肌联蛋白病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mutations in the titin gene (TTN) cause a wide spectrum of genetic diseases. The interpretation of the numerous rare variants identified in TTN is a difficult challenge given its large size. OBJECTIVE: To identify genetic variants in titin in a cohort of patients with muscle disorders. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 9 patients with titinopathy and 4 other patients with possibly disease-causing variants in TTN were identified. Titin mutations were detected through targeted resequencing performed on DNA from 504 patients with muscular dystrophy, congenital myopathy, or other skeletal muscle disorders. Patients were enrolled from 10 clinical centers in April 2012 to December 2013. All of them had not received a diagnosis after undergoing an extensive investigation, including Sanger sequencing of candidate genes. The data analysis was performed between September 2013 and January 2017. Sequencing data were analyzed using an internal custom bioinformatics pipeline. MAIN OUTCOMES AND MEASURES: The identification of novel mutations in the TTN gene and novel patients with titinopathy. We performed an evaluation of putative causative variants in the TTN gene, combining genetic, clinical, and imaging data with messenger RNA and/or protein studies. RESULTS: Of the 9 novel patients with titinopathy, 5 (55.5%) were men and the mean (SD) age at onset was 25 (15.8) years (range, 0-46 years). Of the 4 other patients (3 men and 1 woman) with possibly disease-causing TTN variants, 2 (50%) had a congenital myopathy and 2 (50%) had a slowly progressive distal myopathy with onset in the second decade. Most of the identified mutations were previously unreported. However, all the variants, even the already described mutations, require careful clinical and molecular evaluation of probands and relatives. Heterozygous truncating variants or unique missense changes are not sufficient to make a diagnosis of titinopathy. CONCLUSIONS AND RELEVANCE: The interpretation of TTN variants often requires further analyses, including a comprehensive evaluation of the clinical phenotype (deep phenotyping) as well as messenger RNA and protein studies. We propose a specific workflow for the clinical interpretation of genetic findings in titin.
引用
- Savarese M, Maggi L, Vihola A, et al. Interpreting Genetic Variants in Titin in Patients With Muscle Disorders. JAMA Neurol. 2018. PMID: 29435569. doi:10.1001/jamaneurol.2017.4899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。